Journal article
Pulmonary Aspects of COVID-19
Annual review of medicine, Vol.73(1), pp.81-93
01/27/2022
DOI: 10.1146/annurev-med-042220-014817
PMID: 35084996
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory virus that gains entry via angiotensin-converting enzyme 2 (ACE2) within airway epithelium. Patients exhibit a spectrum of respiratory symptoms from asymptomatic to respiratory failure. Patient factors including obesity, tobacco use, and black race are all associated with increased ACE2 expression and may contribute to increased complications. Consolidation and ground-glass opacities on chest imaging are typical but not specific for coronavirus disease 2019 (COVID-19). Venous thromboembolism occurs infrequently when prophylactic anticoagulation is provided. However, capillary microthrombosis is nearly ubiquitous, suggesting that it contributes to hypoxemia. Remdesivir and glucocorticoids may benefit some hospitalized patients. Many of those afflicted remain symptomatic two weeks following diagnosis and continue to require health care. Total lung capacity, diffusion capacity, and maximal oxygen consumption may be reduced for months in some survivors. Lung transplant offers chronically critically ill patients new hope, and this option may have increasing potential for outpatients with COVID-19-associated fibrosis.
Details
- Title: Subtitle
- Pulmonary Aspects of COVID-19
- Creators
- Kevin C Doerschug - University of IowaGregory A Schmidt - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Annual review of medicine, Vol.73(1), pp.81-93
- DOI
- 10.1146/annurev-med-042220-014817
- PMID
- 35084996
- NLM abbreviation
- Annu Rev Med
- ISSN
- 0066-4219
- eISSN
- 1545-326X
- Language
- English
- Date published
- 01/27/2022
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Internal Medicine
- Record Identifier
- 9984359851102771
Metrics
6 Record Views